PMID- 17286808
OWN - NLM
STAT- MEDLINE
DCOM- 20070315
LR  - 20200418
IS  - 0906-6705 (Print)
IS  - 1600-0625 (Electronic)
IS  - 0906-6705 (Linking)
VI  - 16
IP  - 3
DP  - 2007 Mar
TI  - Oxymetazoline modulates proinflammatory cytokines and the T-cell stimulatory 
      capacity of dendritic cells.
PG  - 171-8
AB  - The nasal decongestant oxymetazoline (OMZ) is frequently used in the topical 
      treatment of rhinitis/sinusitis. As proinflammatory cytokines play a critical 
      role in the development and maintenance of local inflammation, the aim of this 
      study was to investigate the influence of OMZ on immune cells in order to 
      diminish the mucosal infiltration of the nose. Peripheral blood mononuclear cells 
      (PBMC) from buffy coats of healthy volunteers were isolated and stimulated in the 
      presence or absence of OMZ. In addition, monocyte-derived dendritic cells (DC) 
      were generated and different concentrations of OMZ were added. DC phenotype and 
      their T-cell stimulatory properties were analysed. The vasoactive substance OMZ 
      showed a concentration dependent inhibitory effect on T-cell activation as well 
      as a dominant effect on T-cell stimulatory properties of DC. Low concentrations 
      of OMZ inhibited the proliferation of polyclonally activated T cells. In 
      addition, secretion of proinflammatory mediators such as the cytokines 
      interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF alpha), IL-6 and 
      IL-8 were inhibited in the presence of physiological doses of OMZ. Interestingly, 
      the addition of IL-6 to DC-T-cell co-culture was able to completely restore 
      T-cell proliferation. In conclusion, these findings indicate that the 
      anti-inflammatory properties of OMZ are partially mediated by the inhibition of 
      proinflammatory cytokines as well as reduced T-cell stimulatory capacity of DC 
      resulting in a repressed stimulation of T cells. Therefore, the therapeutic 
      benefit of OMZ can be explained in part by its immunomodulating effects in the 
      topical treatment of nasal inflammation.
FAU - Tuettenberg, Andrea
AU  - Tuettenberg A
AD  - Department of Dermatology, University of Mainz, Mainz, Germany. 
      tuettis@hotmail.com
FAU - Koelsch, Stephan
AU  - Koelsch S
FAU - Knop, Jurgen
AU  - Knop J
FAU - Jonuleit, Helmut
AU  - Jonuleit H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Exp Dermatol
JT  - Experimental dermatology
JID - 9301549
RN  - 0 (Cytokines)
RN  - 0 (Nasal Decongestants)
RN  - 8VLN5B44ZY (Oxymetazoline)
SB  - IM
MH  - Cells, Cultured
MH  - Cytokines/*antagonists & inhibitors
MH  - Dendritic Cells/*drug effects/immunology
MH  - Dose-Response Relationship, Drug
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Flow Cytometry
MH  - Humans
MH  - Immunomagnetic Separation
MH  - Leukocytes, Mononuclear/cytology/drug effects
MH  - Lymphocyte Activation/drug effects
MH  - Nasal Decongestants/*pharmacology
MH  - Oxymetazoline/*pharmacology
MH  - Rhinitis/drug therapy
MH  - T-Lymphocytes/*drug effects/immunology
PMC - PMC7163528
EDAT- 2007/02/09 09:00
MHDA- 2007/03/16 09:00
PMCR- 2020/04/17
CRDT- 2007/02/09 09:00
PHST- 2007/02/09 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2007/02/09 09:00 [entrez]
PHST- 2020/04/17 00:00 [pmc-release]
AID - EXD527 [pii]
AID - 10.1111/j.1600-0625.2006.00527.x [doi]
PST - ppublish
SO  - Exp Dermatol. 2007 Mar;16(3):171-8. doi: 10.1111/j.1600-0625.2006.00527.x.